There is nothing more toxic to shareholders than a poster

New Post Public Reply Private Reply Replies (1) Message Board
BruceLake
563
There is nothing more toxic to shareholders than a poster that pretends to know it all but is in fact just a smart-ass that continually speaks from his butthole.

Quote:
What happened to the ROTH conference? nothing manifested,..nothing ! which is why in their most recent filing they specified that they 'had no ongoing talks or negotiations' with interested parties or investors.


What the aforementioned poster fails to comprehend is that the 2019 ROTH conference was held during March 17-19. Regardless of the outcome of the conference it would have been too soon to report it in the 10-K filed on April 1, 2019. Not to mention that the 10-K report is for the fiscal year ended December 31, 2018.

Furthermore a poster that has a penchant for spewing garbage out of you know where, seldom gives specific reference as to exactly where the “quote” came from and its context. The poster also fails to understand that every company has an obligation not only to tell the truth, it also has an obligation to point out “Risk Factors” and to be cautious about forward looking statements. Look at any 10-K and it will be readily obvious that over 50% of the pages, are specifically written to address their SEC obligations. They are written in such a way as to scare the heck out of most investors, especially if they are taken literally. Fact is that there is always an element of risk with any investment, especially with an R&D company that is relatively speaking still at the early stages.

Here is the December 31, 2018 10-K filed on April 1, 2019

https://www.marketwatch.com/investing/Stock/o...amp;type=1

The following quote is from the first paragraph on page 55.

Quote:
Outlook

According to management estimates, our liquidity resources as of December 31, 2018 will not be sufficient to maintain our planned level of operations at least through March 31, 2020. We will need to seek additional capital for the purpose of implementing our business strategy and managing our business and developing drugs. Conducting clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. We have not yet generated any revenues from its current operations, and therefore are dependent upon external sources for financing our operations. We will require significant additional financing in the near future. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements as well as the ability to obtain financing will depend on many factors, including those listed under “RISK FACTORS” beginning on page 25 of this Form 10-K. As of December 31, 2018, we have an accumulated deficit of $27.2 million. In addition, in each of the years ended December 31, 2017 and 2018, we reported losses and negative cash flows from operating activities.

We currently have no agreements, arrangements, or understandings with any person to obtain funds through bank loans, lines of credit, or any other sources. Until we can generate significant continuing revenues, we expect to satisfy its future cash needs through debt or equity financings, or by out-licensing its distribution rights. We cannot be certain that additional funding will be available to it on acceptable terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of its development and commercialization efforts.

We address our liquidity issues by implementing initiatives to raise additional funds as well as other measures that it believes will allow it to continue as a going concern.


Let’s focus on the last sentence, and see what initiatives the company comes up with. If they don't and remain silent, then we'll have no choice but to re-evaluate the situation.

OWC Pharmaceutical Research Corp. (OWCP) Stock Research Links

OWCP Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Leo Cancer Care's Upright Radiotherapy Milestone

Updated Category News Views 4

Upright Radiotherapy: Breaking Tradition in Cancer Care Here's a twist in the world of cancer treatment folks weren't exactly expecting. Leo Cancer Care has flipped the script by taking radiotherapy from a concept to an actual clinical reality with their Upright Platform. Yes, we're talking about standing up while getting treated, and it's not just a gimmick—it's a game...

Continue Reading
Quay Shines in 2026 Prescription Sunglasses Lineup

Updated Category News Views 5

Spotlight on Quay: A Fashion-Forward Prescription Glasses that make you look good and actually correct your vision? That's the holy grail right there. Consumer365 just put Quay front and center in their 2026 rundown of the best prescription sunglasses out there. Let's break this down and see what's got folks buzzing. Diving into Style and Substance Now, if you're like me,...

Continue Reading
Fuse Oncology Showcases New iRT Workflow at ASTRO

Updated Category News Views 4

Revolutionizing Charge Capture in Oncology Fuse Oncology's latest showcase at the ASTRO 2026 Annual Meeting isn't just about flashy presentations—it's looking to change how radiation oncology departments handle complex workflows. If you've ever delved into the maze of oncology billing, you know it's rife with opportunities for errors and inefficiencies. Skip one charge,...

Continue Reading
Synagro Technologies Faces Lawsuit Over Unpaid Expenses

Updated Category News Views 6

Another Day, Another Lawsuit in Corporate America When it rains, it pours, especially in the corporate world where companies occasionally seem to forget they're playing with other people's livelihoods. Now, it's Synagro Technologies, Inc. facing the music. The company is under fire from Blumenthal Nordrehaug Bhowmik De Blouw LLP, a law firm well-versed in employee rights...

Continue Reading
Salveo Home Care Faces Class Action Over Labor Violations

Updated Category News Views 5

Another Company Lands in Hot Water Alright, it looks like Salveo Home Care is in the spotlight for all the wrong reasons. The home care provider—which should have been minding its P's and Q's—is now facing a class action suit. Why, you ask? Well, for allegedly skimping on wages and dodging legal obligations that leave their employees hanging dry. The Allegations are...

Continue Reading
Accuray, Samsung Push Boundaries with Imaging Deal

Updated Category News Views 3

In a move that's got the healthcare industry buzzing, Accuray Incorporated (NASDAQ: ARAY) announced its partnership with Samsung NeuroLogica to supercharge the CyberKnife® System. This isn't just another collaboration; it's a strategic pivot to advance imaging capabilities, marrying Samsung's volumetric innovations with Accuray's established precision in robotic...

Continue Reading
AI Memory Growth Pushes Limits at GMIF2026 Summit

Updated Category News Views 3

The Memory and Storage Race in the AI Era The 5th GMIF2026 Innovation Summit wrapped up in Shenzhen, and boy, was it a heavyweight bout. You could practically feel the tension in the room as industry giants sparred over the future of memory and storage in AI. This wasn't just another trade show pow-wow; this was a strategic chess match over where AI infrastructure is...

Continue Reading
DKS Facing Class Action Over Stock Slump Allegations

Updated Category News Views 3

A Burst Bubble at DICK'S Sporting Goods Grit your teeth and hang on—DICK'S Sporting Goods has stumbled, and investors are supposed to just weather the storm. From September 8, 2025, through August 24, 2026, if you held DICK'S shares, you've got some explaining to do, or at least you better start reading the fine print. Take note, folks: the deadline to file for lead...

Continue Reading
Revamping Children's Radiotherapy: Leo Cancer Care's Vision

Updated Category News Views 5

The latest buzz in pediatric radiotherapy is shaking things up, and it’s all thanks to a game-changing shift in how treatment is delivered to kids. We're eyeballing Leo Cancer Care's innovative approach that might just redefine how these young patients face their battles. Standing Tall: A New Chapter in Proton Therapy In June, Stanford Medicine dished out the first...

Continue Reading
IASO's FUCASO Shows Robust Results in 2026 Study

Updated Category News Views 6

IASO's Groundbreaking Results Stir Ripples in Oncology Folks, let me paint the picture here with the mighty, nitty-gritty details straight from the heart of China. The 2026 IMS Annual Meeting held a gem that could redefine how investors see the course of hematologic malignancy treatments. IASO Bio dropped some heavy data, showing their fine product, FUCASO, in a...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Encouraged to Join Ibotta Class Action at Gross Law Firm

Updated Category News Views 130

Investors Urged to Take Action in Ibotta Class Action Lawsuit If you have invested in Ibotta, Inc. (NYSE: IBTA), it may be time to pay attention. Shareholders are being encouraged to take part in a class action lawsuit that seeks to address the alleged wrongdoings associated with the company's public offering. This initiative is spearheaded by The Gross Law Firm, which...

Continue Reading
TOMI Environmental Solutions Welcomes Harold W. Paul to Board

Updated Category News Views 197

Strategic Board Appointment at TOMI Environmental Solutions TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a key player in the realm of disinfection and decontamination technologies, recently announced an important addition to its Board of Directors. Harold W. Paul has been appointed to this role, a move that is expected to have a significant positive impact on the...

Continue Reading
MaxCyte's Innovative Collaboration with Moonlight Bio on T Cell Therapies

Updated Category News Views 170

MaxCyte Forms Strategic Alliance with Moonlight Bio MaxCyte, Inc. (Nasdaq: MXCT), a pioneering cell-engineering organization, has recently announced a significant collaborative effort with Moonlight Bio, a Seattle-based company focused on pioneering preclinical-stage T cell therapies. This partnership will leverage MaxCyte’s advanced technologies to propel the...

Continue Reading
ZenaTech Showcases Drone Innovations and Future Strategy

Updated Category News Views 114

Revolutionizing Drone Services and Defense Innovations VANCOUVER, British Columbia — ZenaTech, Inc. (NASDAQ: ZENA) (BMV: ZENA) (FSE: 49Q) stands at the forefront of technological solutions, focusing on the exciting realm of Drone as a Service (DaaS) as well as commercial drone developments catering to various industries. The company recently announced its participation...

Continue Reading
Lavu's CEO to Share Insights on AI and Payment Innovations

Updated Category News Views 126

Lavu's CEO to Share Insights on AI and Payment Innovations Lavu, a trailblazer in restaurant AI platforms, is gearing up for an enlightening presentation featuring its CEO, Saleem S. Khatri. He will be a keynote speaker at an upcoming event focusing on the intersection of fintech, AI, and payment systems. A Discussion on Restaurant Operations and Payments The session,...

Continue Reading